Recent events
Recent events tied to this brand in public sources.
Back to profile59 entries · Page 1 of 3
2026
FDA authorizes Roche Elecsys HBsAg II quant II RxDx assay
The U.S. Food and Drug Administration authorized the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic device to help select patients for treatment and assist with monitoring during treatment.
2026
Roche acquires rights to Hansoh Pharma ADC portfolio
Roche acquired rights to a portfolio of antibody-drug conjugates developed by Hansoh Pharma for $510 million. Hansoh will control early development through completion of the first clinical phase; Roche will then take over globally except in mainland China, Hong Kong, Macao and Taiwan.
2026
Hansoh Pharma and Roche announce ADC collaboration
Hansoh Pharma announced a strategic collaboration and licensing agreement with Roche for new antibody-drug conjugate projects. Hansoh will lead early development through completion of global Phase Ia trials and retains development, registration and commercialization rights in mainland China, Hong Kong, Macau and Taiwan; Roche will lead further development elsewhere.
2022
Roche launches a late-stage gantenerumab trial with research institutions
Roche said it was launching a new late-stage clinical trial of its gantenerumab treatment for Alzheimer's disease with three research institutions. The trial aims to evaluate whether the treatment can slow disease progression in people with the earliest biological signs of the disease.
2022
FDA approves Vabysmo for retinal diseases
The US FDA granted approval to Roche’s Vabysmo (faricimab) for treating wet age-related macular degeneration and diabetic macular edema.
2021
Recursion, Roche and Genentech announce neuroscience and oncology collaboration
Recursion announced a collaboration with Roche and Genentech to use machine learning, high-content screening and Recursion's technology-enabled drug-discovery platform to identify novel targets and advance medicines in neuroscience and an oncology indication. Roche and Genentech may initiate up to 40 programs under the agreement.
2021
Roche completes acquisition of TIB Molbiol
Roche completed its share purchase agreement, acquiring all outstanding shares of TIB Molbiol Group. TIB Molbiol will operate as a subsidiary of Roche's Diagnostics division.
2021
Flywheel platform integrated by Roche and Genentech
Flywheel announced that Roche and Genentech had integrated its platform to ingest, classify, standardize, curate and analyze medical imaging data.
2021
Roche launches Avenio tumor tissue genomic profiling kit
Roche launched the Avenio Tumor Tissue Comprehensive Genomic Profiling Kit, jointly developed with Foundation Medicine. The kit is designed to let laboratories expand in-house oncology research; the article says it is set to launch in Europe, North America, Asia and South America.
2021
Roche and Ibex announce digital pathology collaboration
Roche announced an agreement with Ibex Medical Analytics to jointly develop an embedded image-analysis workflow that lets pathologists access Ibex's AI tools through NAVIFY Digital Pathology.
2021
Roche and PathAI announce digital pathology collaboration
Roche announced a development and distribution agreement with PathAI to jointly develop an embedded image-analysis workflow for pathologists, making PathAI algorithms accessible within NAVIFY Digital Pathology.
2021
Shape Therapeutics and Roche enter gene therapy collaboration
Shape Therapeutics entered a multi-target strategic collaboration and licence agreement with Roche to develop gene therapies for targets in Alzheimer’s disease, Parkinson’s disease, and rare diseases. Shape will conduct preclinical research, while Roche will be responsible for development and worldwide commercialisation of products potentially developed through the alliance.
2021
Fresenius filed patent review petitions challenging rheumatoid arthritis patents
Fresenius Kabi USA and Fresenius Kabi SwissBioSim filed Inter Partes Review petitions challenging two patents assigned to Chugai, Roche, and Genentech, asserting that the relevant claims were invalid as anticipated or obvious. These are allegations in the petitions, not a reported decision on their merits.
2021
BioReference announces acquisition of Ariosa’s U.S. prenatal testing business
BioReference Laboratories announced that it had acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche.
2021
mySugr app launches in Thailand
Roche announced that the mySugr app was available in Thailand in English, allowing users to track diabetes data on Apple or Android smartphones.
2021
Roche terminates collaboration and license agreement with 4DMT
4D Molecular Therapeutics announced that Roche terminated their collaboration and license agreement covering certain rights to 4D-110; 4DMT said it would regain full rights to the candidate as a result.
2021
Roche announces expanded cancer-care partnership in Ghana
Roche announced a partnership with Ghana’s government and Ministry of Health to expand access to oncology services, develop cancer-care infrastructure at hospitals, and support provider training and community awareness.
2021
First cancer treatment centre opens at Cape Coast Teaching Hospital
The first of three planned cancer treatment centres opened at Cape Coast Teaching Hospital in Ghana, alongside cold-chain infrastructure to support storage of cold-chain products. The centre was launched through Roche’s partnership with Ghana’s government.
2021
China approves investigational new drug application for combination therapy
TransThera reported that China's National Medical Products Administration had recently approved the investigational new drug application for the TT-00420 and atezolizumab combination therapy.
2021
TransThera and Roche enter collaboration to evaluate TT-00420 combination therapy
TransThera announced that it had entered into a collaboration agreement with Roche to explore combining TT-00420 and atezolizumab for treating patients in China with gastrointestinal tract cancers.